ETON News and Press, Eton Pharmaceutcials Inc. From 08/11/22

Eton Pharmaceuticals press release ( NASDAQ: ETON ): Q2 GAAP EPS of -$0.06 misses by $0.09 . Revenue of $7.4M (+141.0% Y/Y) misses by $0.36M . For further details see: Eton Pharmaceuticals GAAP EPS of -$0.06 misses by $0.09, revenue of $7.4M misses by $0....

Total Q2 2022 revenue of $7.4 million, up 139% from prior year Recently launched ALKINDI SPRINKLE ® and Carglumic Acid continue to show robust growth Divestiture of hospital products division to focus on rare disease strategy U.S. Food and Drug Administration (FDA) Ap...

DEER PARK, Ill., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2022 financial results on Thursday, A...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Eton Pharmaceuticals (NASDAQ: ETON ) stock is on the rise Monday as investors react to news of approval from the U.S. Food and Drug Administration (FDA) for Zonisade. Zonisade is Eton Ph...

The shares of Eton Pharmaceuticals ( NASDAQ: ETON ), company focused on rare diseases added ~20% in the pre-market Monday after the announcement of FDA approval for Zonisade (zonisamide oral suspension) for the treatment of partial seizures. "ZONISADE™ is the fi...

DEER PARK, Ill., July 18, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved ZONISADE&#...

Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today declared that it had agreed to sell its hospital goods to Dr. Reddy’s Laboratories SA, a division of Dr. Reddy&#...

ToughBuilt Industries (TBLT) +87%. Zendesk (ZEN) +52% after report near takeout from PE consortium. Moving iMage Technologies (MITQ) +39% authorizes $1 Million Share Repurchase Program. Eton Pharmaceuticals (ETON) +16% hospital products to Dr. Reddy’s for up to...

Eton sold its rights in Biorphen®, Rezipres®, and Cysteine Hydrochloride products for total payments of up to $50 million Going forward, Eton’s commercial portfolio will exclusively focus on products that treat rare diseases Eton’s royalty portfolio is no...

Shares of Eton Pharmaceuticals are down 10% in after-hours trading after the company said that Azurity Pharmaceuticals received a Complete Response Letter from the U.S. FDA for its lamotrigine product candidate. Although Eton (NASDAQ:ETON) sold its neurology portfolio to Azurit...